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Summary
  Introduction:  Several studies have claimed that the estimation of serum cystatin C could be a better marker of 
kidney excretory function than serum creatinine. However, its role in the diagnosis of reduced 
kidney function was not unquestionably confirmed. The aim of this study was to analyze the con-
centrations of serum cystatin C in neonates with sepsis.
  Material/Methods:  Thirty-two neonates (gestational age from 34 to 40 weeks) admitted to the NICU during the first 
14 days of life were enrolled. Serum cystatin C concentrations were estimated by ELISA during 
three successive days in neonates treated for infection. The study group consisted of 9 newborns 
with sepsis, 14 with severe sepsis and 9 with septic shock.
  Results/Discussion:  At the beginning of the observational period the mean serum concentration of cystatin C in the 
study group was 1.35 mg/L (95% CI 1.20–1.49). Surprisingly, the lowest concentration of cy-
statin was observed in patients with septic shock (1.23 mg/L; 95%CI 0.92–1.54) within the ob-
servation period. Higher concentrations were found in neonates with sepsis (1.47 mg/L; 95%CI 
1.04–1.90) and severe sepsis (1.50; 1.12–1.87). There was no correlation between serum cystatin 
C concentration and serum creatinine or gestational age.
    A significant correlation was discovered between chronological age and cystatin C (R=–0.439, 
p=0.01). There was a tendency for cystatin C to decline during the second observational day in 
patients with sepsis (to 1.53 mg/L; 95%CI: 1.19–1.86) and severe sepsis (to 1.32 mg/L; 95%CI: 
1.07–1.57), while a slight insignificant increase in patient with septic shock (to 1.28 mg/L; 95%CI: 
0.88–1.68) was revealed. The interrelation between age and cystatin C concentration disappeared 
in the following days of stay in the NICU. Even in patients who died in the course of septic shock 
the observed changes in cystatin C levels were small and did not exceed those of serum creatinine.
  Conclusions:  Cystatin C is not a useful marker of kidney function in neonates with sepsis.
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Streszczenie
  Wprowadzenie:  Wyniki opublikowanych badań dowodzą, że oznaczanie cystatyny C w surowicy może stano-
wić lepszy marker czynności wydalniczej nerek niż stężenie kreatyniny w surowicy. Jednakże 
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Sepsis is one of the most severe disorders in newborns and 
young infants, responsible for almost one and a half mil-
lion deaths yearly worldwide. Sepsis is typically divided to 
mild sepsis, severe sepsis and septic shock. The latter two 
may lead to multiorgan dysfunction syndrome, and if the 
inflammatory process is not stopped and reversed it may 
eventually cause multiorgan failure and death. Clinical si-
gns and symptoms are not specific in newborns, which 
makes the disease even more difficult to diagnose. Early 
introduction of antibiotic therapy is essential in the mana-
gement of generalized infection.
Symptoms suggesting kidney dysfunction occur relatively 
late, but may quickly be followed by acute kidney insufficien-
cy. Acute kidney injury (AKI) is claimed to be recognized in 
about 50% of septic adult patients. The epidemiological data 
in newborns are missing, but clinical observations confirm 
the above-mentioned numbers. Both systemic inflammation 
and AKI are serious risk factors for unfavorable outcome. 
There are not many research data on kidney function in the 
short-term post-septic period or in long-term follow-up.
As soon as the diagnosis of AKI is made, the treatment in-
cluding adequate hydration, use of diuretics for proper vo-
lume control, and diet can be introduced. Currently, serial 
measurements of serum creatinine and monitoring of diu-
resis are the only methods for assessment of kidney func-
tion. Serial serum creatinine measurements in the early 
postnatal period eliminate the impact of muscle mass va-
riability or gender, but not that of diet and the declining 
effect of impaired creatinine elimination during pregnancy 
[5,7]. Initially raised serum creatinine values in newborns 
gradually decline during the first months, reaching adult 
values by the end of the first year [7]. Additionally, inter-
ference of bilirubin, hemoglobin and ketone bodies with 
creatinine measurements was observed [7].
Extensive research on new, more sensitive and specific mar-
kers has been conducted in the last twenty years. As a result, 
cystatin C was proposed for evaluation of kidney function.
znaczenie tego markera w diagnostyce upośledzonej czynności nerek u noworodków nie zostało 
jednoznacznie wyjaśnione. Celem badania jest analiza stężeń cystatyny C w surowicy u nowo-
rodków leczonych z powodu sepsy.
 Materiał/Metody:  Do badań włączono 32 noworodki (wiek płodowy 34–40 tygodni) przyjęte do Oddziału Intensywnej 
Terapii i Patologii Noworodka w ciągu pierwszych 14 dni życia. Stężenie cystatyny C oznaczono 
metodą ELISA w 3 kolejnych dobach leczenia z powodu zakażenia. Wśród analizowanych no-
worodków u 9 rozpoznano sepsę, u 14 – ciężką sepsę, a u 9 – wstrząs septyczny.
 Wyniki/Dyskusja:  W chwili włączenia do obserwacji średnie stężenie cystatyny C wynosiło 1,35 mg/L (95% CI 
1,20–1,49). Nieoczekiwanie najniższe wartości cystatyny C obserwowano u pacjentów, u których 
w kolejnych dniach rozwinął się wstrząs septyczny – 1,13 mg/L (95% CI 0,91–1,34). Wyższe war-
tości stwierdzono u noworodków z sepsą 1,51 mg/L (95% CI 1,18–1,84) i ciężką sepsą 1,38 mg/L 
(95% CI 1,13–1,63). Nie wykazano korelacji ze stężeniem kreatyniny w surowicy oraz wiekiem 
płodowym. Stwierdzono natomiast istotną korelację pomiędzy wiekiem chronologicznym a stę-
żeniem cystatyny C (R=–0,439, p=0,01). W kolejnych dniach obserwacji wykazano obniżanie się 
stężeń cystatyny C u chorych z sepsą (1,34 mg/L; 95% CI 0,89–1,78) i ciężką sepsą (1,24 mg/L; 
95% CI 1,00–1,48), podczas, gdy u pacjentów we wstrząsie septycznym obserwowano wzrost 
wartości, choć niewielki i nieistotny statystycznie (1,25 mg/L; 95% CI 0,97–1,53). Zależność po-
między wiekiem a stężeniem cystatyny C zanikała w kolejnych dniach obserwacji. Nawet u pa-
cjentów, którzy zmarli w przebiegu wstrząsu septycznego, obserwowane zmiany w stężeniu cy-
statyny C były niewielkie i nie przekraczały zmian w stężeniu kreatyniny.
  Wnioski:  Cystatyna C nie jest przydatnym parametrem uszkodzenia nerek u noworodków z sepsą.
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       -               -               -               -               -       Cystatin C (CystC), a 120-amino acid protein, is a cyste-
ine protease inhibitor produced by all nucleated cells at 
a constant rate [1,13]. CystC is filtered in the glomeru-
lus, reabsorbed and degraded by epithelium of proximal 
tubes, and passed into the urine [19,21,22]. The role of 
CystC in the diagnosis of reduced kidney function has not 
been confirmed in neonates. It is known that CystC does 
not cross the placenta and should then reflect only the in-
fant’s own renal function [7]. On the other hand, marke-
dly higher concentrations of CystC were revealed shor-
tly after delivery, caused by failure of placental removal. 
At birth, CystC concentration is higher than in adults and 
decreases within 2 months [7]. The reference values pro-
posed by Finney [7] were defined as follows: mean value 
1.37 (mg/L) with range 0.81–2.32 [7]. Armangil [2] me-
anwhile reported 1.25–2.84 mg/L (mean 1.8±0.3) on the 
first day of life followed by a significant decrease on the 
third day (mean: 1.65±0.3 mg/L).
Studies performed in adults showed a strong correlation be-
tween CystC and GFR [3,9,10,18], and these findings were 
confirmed in children and newborns [4,11]. The lack of in-
fluence of muscle mass (approx. ¼ of body weight) or in-
flammatory status on CystC value is considered to be an 
advantage [1,10,18], and allows this marker to be used in 
GFR evaluation [7]. Body weight, gender, diet, hydration 
and nutritional status have no influence on CystC concen-
tration, but thyroid function may have some impact [5].
The aim of this study is to analyze the concentrations of 
cystatin C in neonates suffering from sepsis, intensively 
treated at the NICU, and to compare cystatin C values with 
creatinine concentration.
MaterIal and Methods
Thirty-two neonates in the first 14 days of life, diagnosed 
with sepsis based on clinical symptoms and/or clinical 
history with risk factors of infection, confirmed later by 
positive microbiological blood culture in 24 cases, were 
enrolled. Sepsis (N=9) was defined as SIRS and eviden-
ce of infection (clinical symptoms or positive blood cul-
ture) and severe sepsis (N=14) was identified when the 
course of sepsis was complicated by dysfunction of two 
or more organs or systems. Septic shock (N=9) was reco-
gnized when the decrease in blood pressure occurred to-
gether with symptoms of compromised peripheral blood 
perfusion. All studied patients were outborns and were 
admitted to a single, third level university children’s ho-
spital from home (A&E department) or transferred to the 
unit from other hospitals by a neonatal ambulance trans-
port service. Clinical evaluation of the study group is pre-
sented in Table 1. Clinical condition at the moment of in-
clusion was objectified using SNAP (Score for Neonatal 
Acute Physiology) and the mean value for the study gro-
up was 9.2 (7.3–11.0).
Inclusion criteria consisted of gestational age equal to or 
higher than 34 weeks of gestation and signs and symptoms 
of neonatal sepsis. Malformations of urinary system and 
confirmed severe perinatal asphyxia were the exclusion 
criteria. The study group consisted of 20 males and 12 fe-
males. The average gestational age was 37 weeks (range: 
34–40) and the average birth weight was 2920 g (range: 
1720–4470g). Mean Apgar score after 1 minute was 7 po-
ints (range: 1–10), and 8 after 5 minutes (range: 5–10). One 
patient was given 5 points in the Apgar score after 5 mi-
nutes and 1 point after the first minute, but further clinical 
observation and biochemical tests did not confirm perina-
tal asphyxia. The reasons for hospital admission included 
hyperbilirubinemia, failure to thrive, symptoms of respi-
ratory distress and suspected infection. The mean chrono-
logical age on admission was 8 days of life (range: 1–14), 
and the sepsis was diagnosed within 5 days of hospitali-
zation on average (range: 1–13).
Acute kidney injury (AKI) was scored according to the 
RIFLE classification based on serum creatinine (at least 
Initial After 24 hours  After 48 hours
Leucocytes (109/L)   12.3 (9.8–14.8)   10.9 (8.6–13.3)   10.7 (8.6–12.7)
CRP (mg/dL)   69.9 (51.8–88.0)   93.2 (71.6–114.9)   88.8 (65.4–112.2)
Creatinine (mg/dL)   0.88 (0.76–1.01)   0.83 (0.72–0.93)   0.75 (0.66–0.85)
Urea (mg/dL)   23.5 (18.8–28.2)   27.5 (21.4–33.6)   33.5 (21.6–45.4)
Glucose (mg/dl)   94.5 (80.9–108.0)   105.4 (85.6–125.3)   92.0 (79.8–104.2)
Aspartate aminotransferase, AST (IU/L)  300.0 (23–687) Not estimated   678.6 (15–1550)
Alanine aminotransferase, ALT (IU/L)   89.0 (10–187) Not estimated  163.0  (6–351)
Total protein (g/L)   44.8 (41.8–47.8)   40.5 (36.3–44.7)   39.7 (36.8–42.7)
Albumin (g/L)   28.1 (25.4–30.8)   25.5 (22.8–28.2)   24.1 (22.3–25.8)
Blood pressure (mmHg)  51.0 (46–56)  53.0 (49–58)  55.0 (50–60)
Heart rate (1/min)   145.0 (136–154)   153.0 (147–159)   152.0 (144–161)
Lactate (mg/dL)   3.6 (2.6–4.6)   4.5 (2.2–6.8)   3.0 (2.0–3.9)
Amino acid supplementation (g/kg/d)   0.94 (0.58–1.30)   1.61 (1.36–1.86)   1.73 (1.43–2.02)
Table 1. Clinical evaluation of the study group (N=32) – mean values (95%CI)
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changes after admission to the NICU [15].
The study protocol was approved by the Institutional 
Bioethics Committee. The protocol did not allow for any 
changes from the basic algorithm of diagnosis and treat-
ment accepted in the unit only for the purpose of this stu-
dy. All included patients were cared for and treated in the 
standard way, and the preservation of some samples of se-
rum for further biochemical analysis was the only exception.
All study participants were screened for microbiological colo-
nization on admission and basic septic screening was perfor-
med, including CBC with blood smear, CRP, glucose, lactate, 
electrolytes and blood culture, as well as basic biochemical 
evaluation including creatinine, total protein, serum albumin 
and bilirubin. Urinalysis and urine culture were also perfor-
med. Serum samples were collected after the routine tests 
were completed, and frozen to –70°C in polypropylene tubes.
The observational period started when the patient presen-
ted evident clinical symptoms of infection and antibio-
tic therapy was introduced. The standard protocol inclu-
ded biochemical screening (glucose, lactate, creatinine, 
aspartate aminotransferase [AST], alanine aminotrans-
ferase [ALT]), CBC and ABG every second day or more 
often, according to clinical requirements. Cystatin C me-
asurements were performed by ELISA according to the 
manufacturer’s instructions (BioVendor, Modrice, Czech 
Republic). Creatinine was measured in serum samples by 
the Jaffe method (Olympus AU 640).
Intra and inter-assay coefficients of variability were 
5.0–9.6% and 4.8–6.2% for high and low concentrations, 
respectively.
Statistical analysis
STATISTICA 8.0 (StatSoft Polska, Kraków, Poland) so-
ftware was used for statistical analysis. All presented data 
were expressed as means and 95% confidence intervals. 
Normality of distribution was tested with the Kolmogorov-
Smirnov test. Mann-Whitney U pair-wise comparison for 
independent variables and Wilcoxon pair-wise comparison 
for dependent variables were used as appropriate. Chi2 test 
and Chi2 test with Yates’ correction were used to compare 
distributions between groups. Correlation coefficients were 
calculated according to Spearman. The p values <0.05 were 
considered as statistically significant.
results
At the time of enrolment the mean serum concentration 
of CystC was 1.35 mg/L (95% CI 1.20–1.49). The lowest 
concentration was 1.23 mg/L (95% CI 0.92–1.54) and was 
observed in patients who developed septic shock during 
the following days. Surprisingly, slightly higher concentra-
tions were found in neonates with sepsis (1.47 mg/L; 95% 
CI 1.04–1.90) and severe sepsis (1.50; 1.12–1.87).
Analysis of demographic factors revealed lack of a corre-
lation between CystC and gestational age, 5’ minute Apgar 
score, birth weight and gender. A significant correlation 
was found between chronological age and CystC levels 
(R=–0.439, p=0.01), but the interrelation disappeared on 
the following days of hospitalization. There was also no 
correlation with serum creatinine (Figure 1).
Comparison of creatinine and CystC values at successive 
time points (at the beginning of the observational period, 
and after 24 and 48 hours) in the three subgroups of pa-
tients (groups A, B and C) showed some statistically si-
gnificant differences of creatinine concentrations betwe-
en the subgroups. Such results were not found in regard 
to CystC (Table 2).
During the 3-day observation period a tendency for CystC 
level to decline in patients with sepsis (1.53 mg/L, 95%CI: 
1.19–1.86) and severe sepsis (1.32 mg/L; 95%CI: 1.07–1.57) 
was found. In patients with septic shock CystC levels in-
significantly increased (1.28 mg/L; 95%CI: 0.88–1.68) – 
Figure 2. Even in patients who died in the course of sep-
tic shock the observed changes in CystC were small and 
did not exceed those of serum creatinine.
dIscussIon
The results of the study revealed that assessment of CystC 
is not better, and in fact seems to be even worse than that 
of serum creatinine, in newborns treated for sepsis in the 
detection of sepsis-related AKI.
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only of newborns admitted to the hospital on their first 
days of life, not older than 15 days. On admission their cli-
nical condition was diverse, ranging from very stable to 
unstable with symptoms of cardio-respiratory dysfunction.
Regardless of the severity of clinical condition the initial 
serum creatinine levels were elevated, which is considered 
physiological in newborns in their first 2–3 days of life. It 
has been shown that serum creatinine in the first three days 
of life revealed the kidney status of the mother, as creati-
nine is eliminated through the placenta along a gradient 
[2]. Analysis of serum creatinine concentrations separate-
ly in all three groups of patients revealed higher values in 
newborns suffering from severe sepsis and septic shock, 
indicating AKI in some patients, even taking into account 
limitations such as maternal kidney status, chronological 
age and muscle mass.
Sepsis 
(N=9) (A)
Severe sepsis 
(N=14) (B)
Septic shock 
(N=9) (C)
Statistical 
significance
GA 36 (35–38) 37 (36–38) 39 (38–40) A vs C p=0.02
Birth weight (g) 3146 (2551–3741) 2679 (2358–3000) 3284 (2905–3663) NS
Day of life 10 (6–14) 7 (5–9) 8 (5–12) NS
SNAP (pts) 6.6 (4.3–8.9) 9.3 (6.7–11.9) 11.7 (6.1–17.3) A vs C p=0.003
Creatinine (mg/dL)
Initial 0.66 (0.42–0.90) 0.95 (0.78–1.13)  0.93 (0.64–1.22) A vs B p=0.03
A vs C p=0.04
After 24 hours 0.68 (0.48–0.87) 0.86 (0.71–1.02) 0.92 (0.63–1.20) A vs B p=0.03
After 48 hours  0.56 (0.42–0.70) 0.77 (0.66–0.88)  1.02 (0.76–1.27) A vs B p=0.02
A vs C p=0.01
B vs C p=0.05
48 hours vs Initial
p=0.04 
48 hours vs Initial 
p=0.04
NS
Cystatin C (mg/L)
Initial 1.47 (1.04–1.90) 1.50 (1.12–1.87) 1.23 (0.92–1.54)  NS
After 24 hours 1.53 (1.19–1.86)  1.32 (1.07–1.57)  1.28 (0.88–1.68)  NS
After 48 hours  1.43 (1.05–1.81)  1.31 (1.05–1.58)  1.21 (0.95–1.47)  NS
NS NS NS
Lactate [mg/dL]
Initial 2.61 (1.18–4.04)  4.02 (2.49–5.54)  4.00 (0.70–7.30)  NS
After 24 hours 2.05 (1.47–2.62)  3.23 (2.26–4.19)  11.77 (1.83–25.67)  A vs C p=0.01
B vs C p=0.03
After 48 hours 1.81 (1.30–2.32)  2.92 (1.86–3.98)  4.57 (1.50–9.99)  NS
NS 48 vs 24 hours
p<0.05
24 hours vs Initial 
p<0.006
Table 2.  Values of creatinine and cystatin C in three subgroups of newborns at successive time points. Mean value, 95%CI and statistical significance of 
differences between the subgroups A, B and C (Mann-Whitney U test) are presented
AKI patients (N=8) Non-AKI patients (N=24) Statistical significance 
Initial 1.47 (1.23–1.71) 1.39 (1.13–1.65) NS
After 24 hours 1.55 (1.06–2.030 1.28 (1.13–1.42) NS
After 48 hours  1.29 (1.13–1.47) 1.33 (1.17–1.48) NS
Table 3.   Serum cystatin C concentration in neonates with and without acute kidney injury (AKI) during the three successive days of observation 
(Mann-Whitney U test), values presented as mean value and 95%CI
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There are few authors reporting on CystC concentrations, 
measured by nephelometric or turbidimetric methods, on 
the first days of life: Novo – 1.70±0.26 mg/L on the first and 
1.51±0.19 mg/L on the third day of life [17]; Finney [7] – 
0.81–2.32 mg/L during the first three months; Harmoinen 
[11] – 1.36–2.23 mg/L in the first week of life; and Treiber 
[20] 1.28–2.66 mg/L on the third day. The range 0.81–2.6 
mg/L detected in our patients corresponds with the abo-
ve data of clinically stable newborns, but measured with 
a different method (ELISA).
In contrast to a suggestion of Nejat et al. [16], who claimed 
that CystC was an effective and earlier surrogate marker of 
decreased renal function than plasma creatinine in a gene-
ral ICU population, we could not confirm that on the basis 
of our results. Recently, Mårtensson et al. reported [14] a 
similar increase in serum CystC and creatinine levels in pa-
tients with AKI and sepsis. Thus the assessment of CystC 
as a functional marker of AKI seems to be useless at least 
in septic newborns. Some authors suggest that CystC is a 
better marker only for detection of chronic kidney injury, 
and that only chronic damage causes a steady and signifi-
cant increase in CystC concentration [6,8,12,22].
The relatively low values found in the most severely ill pa-
tients are rather surprising. Regarding the normal range of 
CystC in newborns, patients with septic shock presented 
values in the lower range or even below. Cystatin C is fo-
und in the lysosomes of every cell, and actively participate 
in protein metabolism inside the cell. The marker is known 
for its resistance to the influence of inflammation. It seems 
that severe inflammatory status may disturb cell metabo-
lism, causing a decrease in concentrations of some sub-
stances. Unfortunately, the literature on the topic is spar-
se, and fails to provide a good explanation.
Recently Måtterson et al. reported that sepsis per se does 
not affect circulating CystC level, and thus is a potential-
ly valuable marker of kidney function, including in septic 
patients. Moreover, this group did not show a correlation 
between CRP and cystatin C values [14].
The main limitation of the study is the lack of glomeru-
lar filtration rate measurement by insulin clearance tech-
nique or similar. Moreover, we did not check the thyroid 
status, although all newborns were screened for congenital 
hypothyroidism. Finally, we did not enroll a group of heal-
thy neonates as the control group. Thus we cannot compa-
re the cystatin C values observed in septic neonates with 
those in healthy subjects.
We conclude that cystatin C is not a useful marker of kid-
ney function in neonates with sepsis.
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